Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation

被引：1
|
作者：
Bouwhuis, M. G.
Suciu, S.
Testori, A.
Santinami, M.
Kruit, W. H.
Punt, C. J.
Sales, F.
Patel, P. M.
Spatz, A.
Eggermont, A. M. M.
机构：
[1] Erasmus MC Univ Med Ctr Rotterdam, Rotterdam, Netherlands
[2] EORTC Data Ctr, Dept Biostat, Brussels, Belgium
[3] European Inst Oncol, Milan, Italy
[4] Natl Canc Inst, I-20133 Milan, Italy
[5] Univ Med Ctr Nijmegen, Nijmegen, Netherlands
[6] Inst Jules Bordet, B-1000 Brussels, Belgium
[7] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
[8] Inst Gustave Roussy, Villejuif, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 06期
关键词：
D O I：
10.1016/S1359-6349(07)70098-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5LB
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [31] Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Enk, Alexander
    Tilgen, Wolfgang
    Loquai, Carmen
    Gogas, Helen
    Haalck, Thomas
    Koller, Josef
    Dummer, Reinhard
    Gutzmer, Ralf
    Brockmeyer, Norbert
    Hoelzle, Erhard
    Sunderkoetter, Cord
    Mauch, Cornelia
    Stein, Annette
    Schneider, Lars A.
    Podda, Maurizio
    Goeppner, Daniela
    Schadendorf, Dirk
    Weichenthal, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4077 - +
  • [32] Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952
    Bouwhuis, M. G.
    Suciu, S.
    Kruit, W.
    Sales, F.
    Stoitchkov, K.
    Patel, P.
    Cocquyt, V.
    Thomas, J.
    Lienard, D.
    Eggermont, A. M. M.
    Ghanem, G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (03) : 361 - 368
  • [33] Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy.
    Krogh, M.
    Christensen, I. J.
    Bouwhuis, M.
    Johansen, J. S.
    Schmidt, H.
    Hansson, J.
    Aamdal, S.
    Testori, A.
    Eggermont, A. M.
    Bastholt, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialaEuro
    Eigentler, T. K.
    Gutzmer, R.
    Hauschild, A.
    Heinzerling, L.
    Schadendorf, D.
    Nashan, D.
    Hoelzle, E.
    Kiecker, F.
    Becker, J.
    Sunderkoeter, C.
    Moll, I.
    Richtig, E.
    Poenitzsch, I.
    Pehamberger, H.
    Kaufmann, R.
    Pfoehler, C.
    Vogt, T.
    Berking, C.
    Praxmarer, M.
    Garbe, C.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (08) : 1625 - 1632
  • [35] Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
    Eggermont, Alexander M. M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew
    Lichinitser, Mikhail
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Di Giacomo, Anna Maria
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul C.
    Lupinacci, Robert
    Krepler, Clemens
    Ibrahim, Nageatte
    Kicinski, Michal
    Marreaud, Sandrine
    van Akkooi, Alexander C.
    Suciu, Stefan
    Robert, Caroline
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 116 : 148 - 157
  • [36] Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
    Kennedy, Oliver J.
    Kicinski, Michal
    Valpione, Sara
    Gandini, Sara
    Suciu, Stefan
    Blank, Christian U.
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Di Giacomo, Anna M.
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    van Akkooi, Alexander C. J.
    Robert, Caroline
    Eggermont, Alexander M. M.
    Lorigan, Paul
    Mandala, Mario
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 165 : 97 - 112
  • [37] Randomized trial of pegylated interferon α-2b monotherapy in haemodialysis patients with chronic hepatitis C
    Russo, MW
    Ghalib, R
    Sigal, S
    Joshi, V
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (02) : 437 - 443
  • [38] Concurrent adjuvant radiotherapy and interferon-α2b for resected high risk stage III melanoma -: a retrospective single centre study
    Gyorki, DE
    Ainslie, J
    Joon, ML
    Henderson, MA
    Millward, M
    McArthur, GA
    [J]. MELANOMA RESEARCH, 2004, 14 (03) : 223 - 230
  • [39] Serum S-100B protein is a strong independent prognostic marker for distant-metastasis free survival (DMFS) in stage III melanoma patients: An evaluation of the EORTC randomized trial 18952 comparing IFNα versus observation
    Suciu, S.
    Ghanem, G.
    Kruit, W.
    Stoitchkov, K.
    Patel, P.
    Delaunay, M.
    ten Hagen, T.
    Musat, E.
    Sales, F.
    Eggermont, A. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
    Daud, A. I.
    Xu, C.
    Hwu, W. -J.
    Urbas, P.
    Andrews, S.
    Papadopoulos, N. E.
    Floren, L. C.
    Yver, A.
    DeConti, R. C.
    Sondak, V. K.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (03) : 657 - 666
12345